“Quality comes from science. If you don’t understand the science, you will never achieve true quality.”
That belief has defined Shukla’s entire journey, from working as a microbiologist handling environmental monitoring and sterility testing to leading operations at Zydus Life Sciences.
One of the most striking parts of the interview was how honestly he spoke about his early career. He shared that when he started working at Nicholas Piramal, his biggest dream was simply to buy a Maruti 800 before retirement. At that time, pharmaceutical microbiology was completely manual. Teams cleaned glassware themselves, handled sterilization processes manually, and even managed aseptic area cleaning without external support.
Those early years shaped his mindset around discipline, accountability, and ownership.
Over time, he kept expanding his expertise, moving from microbiology into IPQA, validation, quality assurance, chemistry labs, and eventually leadership positions across companies including Lupin.
But the turning point in his career came when he made a rare transition from Head of Quality into operations around 2013.
“I felt real quality improvements happen on the shop floor.”
That one decision eventually led him to manage complex injectable manufacturing networks globally, including leading Asia-Pacific injectable operations at Pfizer before returning to Zydus.
The interview also highlighted how rapidly the pharmaceutical industry is shifting toward injectables and biologics, where microbiology and sterility assurance are becoming critical.
“What you cannot see is the most difficult thing to control.”
Shukla explained how contamination risks in aseptic manufacturing cannot always be solved with simple disinfection practices. Instead, companies need stronger contamination control strategies, intervention-free systems, engineering excellence, and better maintenance culture.
He also spoke openly about India’s injectable manufacturing ecosystem. While India dominates oral solid manufacturing globally, he believes injectables require deeper scientific understanding, especially at leadership levels.
Still, he remains optimistic about the future.
“I am confident that in the next 5–10 years, India will become globally respected in injectables.”
Beyond manufacturing, what truly made the conversation stand out was his leadership philosophy.
He believes leadership is not about micromanagement or authority, but about listening to people, empowering teams, and building trust-driven cultures.
“A delayed decision is a denied decision.”
He also shared that culture is non-negotiable. According to him, employees lose motivation not because promotions are delayed, but because organizations fail to act against wrong behavior or poor integrity.
His final message was perhaps the most powerful: “Organizations need preventive maintenance for people, just like machines.”
A simple line, but one that perfectly reflects the kind of leader he has become.
Get Easy Access
Our experts provide real time country to company in depth data, segments data, stats and competitive intellience all under one platform.
Visit dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research and Consulting is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
]]>Johnson & Johnson has secured approval from the U.S. Food and Drug Administration for ICOTYDE
, a once-daily oral therapy designed to treat moderate-to-severe plaque psoriasis. The drug stands out as the first and only oral peptide targeting the IL-23 receptor (IL-23R); introducing a new level of precision in immunology treatments.
A Strategic Shift from Biologics to Precision Oral Therapy
Plaque psoriasis treatment has long relied on injectable biologics that target cytokines such as IL-23.
While effective, these therapies often come with administration challenges and patient hesitancy.
ICOTYDE introduces a novel receptor-level targeting approach, directly blocking IL-23R rather than circulating cytokines.
This mechanism enables more selective immune modulation while offering the convenience of a once-daily oral pill, potentially improving adherence and long-term outcomes.
Robust Efficacy Backed by Clinical Data
Clinical trial data positioned ICOTYDE among the most promising next-generation psoriasis therapies.
A significant proportion of patients achieved PASI 90 and PASI 100 responses, indicating near-total to complete skin clearance within a relatively short timeframe.
Patients not only experienced rapid visible improvement,
but also maintained durable responses over extended treatment periods.
Equally important, the therapy demonstrated a favorable safety and tolerability profile,
with low incidence of serious adverse events; making it suitable for chronic, long-term use.
Market Impact and Future Outlook
The approval strengthens Johnson & Johnson’s position in the highly competitive immunology space.
It also introduces a new competitive dynamic within the IL-23 inhibitor segment, which has been largely dominated by injectable monoclonal antibodies.
ICOTYDE is expected to drive high patient adoption, particularly among those seeking effective yet non-invasive alternatives.
Looking ahead, this innovation could accelerate the development of oral peptide-based therapies across other autoimmune conditions, reshaping treatment paradigms beyond psoriasis.
Bottom Line:
ICOTYDE represents more than a new drug—it marks a transformational leap toward targeted, convenient, and patient-centric care, setting a new benchmark for oral therapies in chronic inflammatory diseases.
Contact us for news or updates you want: [https://www.towardshealthcare.com/contact-us]
While the total deal value has been disclosed, Lilly has not specified how much will be paid upfront versus milestone-based payments tied to clinical progress.
Why This Acquisition Matters
Traditional CAR-T therapies require extracting a patient’s immune cells, engineering them outside the body, and reinfusing them — a complex and costly process that limits scalability. In contrast, in vivo CAR-T therapies aim to reprogram immune cells directly inside the patient’s body, potentially simplifying manufacturing and expanding access.
Orna Therapeutics has built its platform around engineered circular RNA (oRNA) combined with lipid nanoparticles. This approach is designed to generate CAR-T cells within the body itself, removing the need for ex vivo cell manipulation.
According to Lilly, early experimental data suggests that Orna’s circular RNA platform may provide more durable expression of therapeutic proteins compared to traditional linear RNA approaches. If validated in clinical studies, this could open the door to therapies that are not feasible with existing RNA or cell therapy technologies.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Spotlight on ORN-252
At the center of the acquisition is ORN-252, a CD19-targeting in vivo CAR-T therapy described by Lilly as “clinical trial-ready.” The candidate is being developed for B-cell-driven autoimmune diseases.
Autoimmune disorders such as lupus and certain inflammatory conditions are increasingly being explored as targets for CAR-T therapy. Early autologous CAR-T studies have demonstrated meaningful potential in resetting dysfunctional immune systems. However, cost, manufacturing complexity, and logistical challenges have limited broader implementation.
Francisco Ramírez-Valle, M.D., Ph.D., head of immunology research and early clinical development at Lilly, acknowledged these barriers:
“Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them.”
By integrating Orna’s in vivo platform, Lilly aims to explore a more accessible pathway to immune reprogramming.
A Broader Strategic Trend
Lilly’s move follows a wave of acquisitions in the in vivo CAR-T space:
-
Gilead Sciences acquired Interius BioTherapeutics for $350 million and entered a deal with Pregene worth up to $1.6 billion.
-
AbbVie acquired Capstan Therapeutics for $2.1 billion last year.
-
Bristol Myers Squibb purchased Orbital Therapeutics for $1.5 billion.
-
AstraZeneca acquired EsoBiotec for $1 billion.
These transactions reflect strong industry interest in genetic medicine platforms capable of delivering cell therapies directly inside patients.
Lilly had signaled its intent to explore this area months earlier when it began recruiting leadership focused on CAR-T biology. The Orna acquisition formalizes that strategic direction.
From MIT Research to Big Pharma Integration
Founded in 2021, Orna Therapeutics launched with $100 million in funding and a mission to bring engineered CAR constructs directly to immune cells within the body. The company’s platform is rooted in research from MIT by Alex Wesselhoeft, Ph.D., and Professor Dan Anderson, Ph.D.
Orna has since developed what Lilly describes as a “broad platform” capable of supporting multiple in vivo CAR-T programs — effectively creating a pipeline engine rather than a single-asset play.
Looking Ahead
With this acquisition, Lilly secures full ownership of Orna’s circular RNA platform and in vivo cell engineering capabilities. The company believes this could represent a long-term innovation opportunity in genetic medicine and immune system modulation.
If successful, in vivo CAR-T therapies could redefine how autoimmune and potentially other immune-mediated diseases are treated — offering a more streamlined alternative to today’s cell therapy infrastructure.
The coming years will determine whether circular RNA-based in vivo CAR-T approaches can translate early scientific promise into clinical reality. For now, Lilly has placed a significant strategic bet on the future of genetic medicine.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
]]>The company reported a 100% complete response (CR) rate within one month among all patients treated in this second dose cohort — a remarkable milestone in the treatment of relapsed or refractory (R/R) B-cell NHL, especially among high-risk patients who were ineligible for commercial CD19 therapies, including one participant with Central Nervous System (CNS) lymphoma.
Equally notable, no serious treatment-related adverse events (SAEs) were observed during the trial, underscoring EB103’s favorable safety profile in a population that traditionally faces limited therapeutic options.
About the Second Dose Cohort
The second dose cohort enrolled patients with refractory or relapsed B-cell NHL who had previously failed multiple lines of therapy. Following treatment, a Data and Safety Monitoring Board (DSMB) — an independent expert committee overseeing patient safety and study progress — will review cumulative safety and efficacy data to recommend the Recommended Phase 2 Dose (RP2D) for the next phase of the trial.
The Phase 1/2 STARLIGHT-1 study is a multi-center, open-label, dose-escalation and dose-expansion trial designed to assess both the safety and preliminary efficacy of EB103, an autologous T-cell therapy, in adult patients aged 18 and older with R/R B-cell NHL. Phase 1 focuses on dose escalation and safety evaluation, while Phase 2 aims to explore the therapy’s clinical benefit at the RP2D.
Leadership Remarks
Dr. Cheng Liu, Chief Executive Officer of Estrella Immunopharma, commented on the milestone:
“The completion of the second dose cohort with a 100% CR rate marks a major achievement in our EB103 clinical program. We’re encouraged by the therapy’s excellent safety profile, even in a high-risk patient population — including those with CNS involvement. These findings highlight EB103’s potential as a safe and effective treatment option for patients with limited alternatives. We’re now preparing to advance to the dose extension phase of the STARLIGHT-1 trial.”
Next Steps
Estrella Immunopharma plans to initiate the extension phase of STARLIGHT-1 following DSMB evaluation, moving closer to establishing EB103 as a next-generation T-cell therapy for hard-to-treat hematologic malignancies.
If subsequent phases confirm these early results, EB103 could represent a significant breakthrough in the management of advanced B-cell NHL, potentially redefining therapeutic standards for patients who have exhausted current treatment avenues.
Read Complete News at: https://www.towardshealthcare.com/news/estrella-eb103-phase-1-trial-results
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
]]> clinical research business has unveiled an innovative carbon calculator designed to address the environmental impact of clinical trials, marking a significant step towards sustainability in the healthcare sector.
Source: https://www.towardshealthcare.com/news/thermo-fisher-clinical-trial-carbon-calculator
Reducing Environmental Impact in Clinical Trials
Thermo Fisher’s new clinical trial carbon calculator is a pioneering tool that aims to help biopharmaceutical companies and research sponsors measure and reduce the environmental footprint of their clinical trials. The calculator focuses on providing a detailed assessment of the carbon emissions generated at each stage of a clinical trial, from patient travel to site operations and investigational product manufacturing.
Understanding the Scope of Clinical Trial Emissions
Clinical trials are a cornerstone of medical progress, but they also have a substantial environmental cost. A single phase 3 clinical trial can generate around 3,000 metric tons of CO2 equivalent emissions, which is comparable to the annual emissions of 176 Americans. As the clinical research industry grows, so does its carbon footprint, which can rival the emissions of entire nations, such as the Turks and Caicos or British Virgin Islands. These alarming statistics highlight the need for sustainability within the clinical trial sector.
Statements from Thermo Fisher’s Leadership
Michael J. Cohen, Senior Director of Environmental Sustainability at Thermo Fisher Scientific, emphasized the company’s dual responsibility: to advance human health and protect the planet. He stated, “The industry is dedicated to enhancing human health, and we’re equally liable and hold the responsibility to safeguard the planet. Our new carbon calculator enables sponsors to read the insightful details they need to make sustainable and data-fueled choices in trial design before the fossil fuels and waste are burned.” Cohen further outlined the tool’s primary goal, which is to assist healthcare professionals in identifying areas of clinical trials that can be optimized for sustainability through decarbonization initiatives.
How the Carbon Calculator Works
The carbon calculator is an open-access tool that offers a structured framework for measuring emissions across various stages of clinical trials. This includes emissions resulting from:
● Patient Travel: Transportation to and from trial sites.
● Lab Sample Processing: Emissions from processing clinical samples in laboratories.
● Site Operations: Carbon footprint from the day-to-day activities at clinical trial sites.
● Investigational Product Manufacturing: Emissions tied to the production of the trial medication or device.
The tool allows users to identify the most significant “carbon hotspots” across these stages and compare different study designs in terms of their CO2 equivalent efficiency. By pinpointing these high-emission areas, the carbon calculator helps sponsors develop strategies to mitigate environmental impact without compromising trial quality or regulatory compliance.
Promoting Sustainable Trial Models
One of the key features of the carbon calculator is its support for hybrid or decentralized trial models. These models incorporate virtual visits and remote monitoring, which significantly reduce emissions from travel and on-site activities. By moving parts of the trial to digital platforms, such as remote patient consultations or virtual monitoring, it is possible to significantly lower the carbon footprint, making clinical trials more sustainable.
Collaborative Efforts Towards Sustainability
Thermo Fisher’s commitment to sustainability extends beyond just providing the carbon calculator. The company is actively working with vendors, investigative sites, and sponsors to integrate environmental responsibility into all aspects of clinical trial execution and planning. Through partnerships, Thermo Fisher aims to enhance sustainability across the entire clinical development process, from initial trial design to the final stages of data collection and reporting.
A Call to Action for the Industry
This initiative comes at a critical time when industries worldwide are under increasing pressure to adopt environmentally responsible practices. By providing a tool that quantifies and enables the reduction of emissions, Thermo Fisher is leading the charge in making clinical trials more eco-friendly. As the healthcare industry continues to expand and clinical trials become increasingly globalized, it is clear that integrating sustainability measures will be essential for the future of medical research.
In conclusion, Thermo Fisher’s innovative clinical trial carbon calculator offers a transformative approach to minimizing the environmental impact of clinical trials. By helping sponsors identify and address key areas of emissions, the tool supports the shift towards more sustainable trial models, aligning with broader global efforts to reduce carbon footprints across industries.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
]]>Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for Rybelsus® (oral semaglutide), marking a groundbreaking milestone in diabetes and cardiovascular care. Rybelsus® becomes the first-ever GLP-1 (glucagon-like peptide-1) receptor agonist in oral form to be approved for reducing the risk of major adverse cardiovascular events (MACE)—including heart attack, stroke, and cardiovascular (CV) death, in adults with type 2 diabetes, regardless of prior cardiovascular disease history.
This approval reinforces Novo Nordisk’s leadership in advancing innovative therapies that go beyond glycemic control to address broader health risks in diabetic populations. By expanding the use of oral semaglutide beyond glucose regulation, the company aims to redefine preventive cardiovascular treatment strategies for millions of patients globally.
The Significance of the Approval
The newly approved indication positions Rybelsus® as a key therapy for both primary and secondary prevention of cardiovascular events.
● Primary prevention focuses on managing and lowering risk factors among adults at high risk for cardiovascular complications.
● Secondary prevention targets individuals with existing cardiovascular disease, helping to mitigate further incidents such as heart attack or stroke.
This expanded use underscores the therapeutic versatility of semaglutide, a molecule already recognized for its robust metabolic and cardiovascular benefits.
In addition, Novo Nordisk has submitted a supplemental New Drug Application (sNDA) in the United States for an oral formulation of semaglutide (once-daily) under the brand name Wegovy®, targeting the treatment of obesity. If approved, this could further extend semaglutide’s reach into weight management and metabolic care.
Insights from the SOUL Clinical Trial
The FDA’s decision is strongly supported by findings from the Phase 3b SOUL trial, which evaluated the cardiovascular outcomes of oral semaglutide (14 mg) alongside standard care in adults with type 2 diabetes at high cardiovascular risk.
The primary endpoint was the time to the first occurrence of a MACE, defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction (heart attack), or nonfatal stroke.
Results demonstrated:
● MACE occurred in 12.0% (579/4,825) of participants treated with semaglutide, compared to 13.8% (668/4,825) in the placebo group.
● This translates to a statistically significant 14% relative risk reduction in MACE over a four-year period, emphasizing the meaningful cardiovascular protection offered by oral semaglutide.
These findings add to a growing body of evidence from real-world data and large-scale randomized clinical trials, establishing semaglutide as a cornerstone molecule with proven efficacy across multiple therapeutic areas, including diabetes, cardiovascular health, and weight management.
Statements from Novo Nordisk Leadership
Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc., expressed pride in this pivotal achievement:
“Being the only FDA-approved GLP-1 therapy available in a pill form, Rybelsus® has now been recognized for its evident cardiovascular benefits. This marks a new milestone for the future of our oral innovation platform. The semaglutide molecule continues to demonstrate consistent and comprehensive clinical outcomes across multiple large-scale trials, reinforcing its role in improving long-term health for patients.”
Broader Implications for Patient Care
The approval of Rybelsus® for cardiovascular risk reduction represents a significant advancement in the management of type 2 diabetes, where cardiovascular disease remains one of the leading causes of mortality. Oral semaglutide’s unique administration form addresses challenges with injectable GLP-1 therapies, potentially improving patient adherence and accessibility.
With cardiovascular protection now added to its benefits, Rybelsus® strengthens Novo Nordisk’s growing portfolio of semaglutide-based therapies, aligning with the company’s mission to defeat diabetes and chronic disease through innovative science and patient-centric care.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Powering Healthcare Leaders with Real-Time Insights: https://www.towardshealthcare.com/healthcare-intelligence-platform
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
]]>The dual regulatory approvals pave the way for clinical trials to begin in both China and the U.S., accelerating development of this potential breakthrough therapy for advanced gastrointestinal cancers.
What is 7MW4911?
Developed using Mabwell’s proprietary IDDC (Intelligent Design Drug Conjugate) platform, 7MW4911 is a CDH17-focused ADC with three key components:
Mab0727, a monoclonal antibody with fast internalization, low off-target binding, and moderate human/monkey cross-species affinity
A cleavable linker engineered for precise payload release at tumor sites
MF-6, a novel DNA topoisomerase I inhibitor designed to minimize multidrug resistance (MDR), induce bystander killing, and ensure high plasma stability
Together, these components deliver a highly targeted cytotoxic payload directly to tumor cells expressing CDH17, while sparing healthy tissue.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Robust Preclinical Data Supports IND Approval
Mabwell’s preclinical findings, published in Cell Reports Medicine in July 2025, demonstrated that 7MW4911 exhibits tumor-selective cytotoxicity via CDH17-mediated internalization. The study showed promising results across a range of gastrointestinal cancer models, including gastric, pancreatic, and colorectal cancers with varying RAS/BRAF mutations and molecular subtypes.
Key highlights of 7MW4911’s performance:
Overcomes MDR: Outperforms MMAE/DXd-based ADCs in models with ABC transporter-mediated drug resistance
Broad Antitumor Efficacy: Triggers tumor regression even in low to moderate CDH17-expressing tumors
High Stability & Precision: Features a drug-to-antibody ratio (DAR) of 4 and >95% homogeneity
Safety Profile: Demonstrates limited off-target toxicity, no drug accumulation, and a favorable pharmacokinetic profile in preclinical monkey and mouse studies
A Strategic Leap Toward Cancer Innovation
The regulatory green lights from both the NMPA and FDA mark an important step forward for Mabwell’s commitment to fighting severe cancers through precision biologics and next-gen ADCs. The company now looks forward to launching exploratory clinical trials that will further determine the efficacy and safety of 7MW4911 in human subjects.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
]]>The acquisition marks a pivotal expansion for Demetra, a company with over four decades of expertise in prosthesis fixation, orthobiologics, and infection control. With this move, Demetra aims to accelerate innovation in spinal surgery and meet the rising demand for efficient, value-based surgical solutions worldwide.
Boosting Technological and Clinical Capabilities
By acquiring OrthoFundamentals, Demetra significantly strengthens its presence in the spine surgery segment. The deal builds on Demetra’s previous strategic acquisitions, including Switzerland-based Getset Surgical and a key asset purchase from Bespoke Technologies. These past deals brought cutting-edge sterile-packed, single-use procedure kits and 3D-printed titanium implants for ACDF (anterior cervical discectomy and fusion) procedures into Demetra’s growing portfolio.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
The integration of OrthoFundamentals’ single-use implant kits aligns with Demetra’s mission to eliminate reprocessing, reduce the risk of surgical site infections, and improve operating room efficiency especially in ambulatory surgical centers (ASCs), where demand for outpatient spine surgery is rapidly increasing.
Industry Voices Welcome the Merger
Mathew Palmer, Founder and CEO of OrthoFundamentals, expressed optimism about the partnership:
“There was a joint vision and natural synergy between Demetra and us. We identified pain points in spine surgical solutions especially in outpatient ASC settings. With Demetra’s backing, we aim to lead the market with sterile, ready-to-use, single-use systems that make a real difference.”
Ted Bird, Vice President of Demetra Spine, North America, added:
“Demetra is bringing a unique portfolio of ‘surgery-in-a-box’ kits to market fully prepped for hospitals and ASCs. Our goal is to become a leader in the fast-growing outpatient spine surgery market by offering efficient, infection-resistant, and cost-effective solutions.”
A Strategic Leap in Spinal Innovation
With over 3 million lives impacted by Demetra’s orthopedic solutions globally, the creation of Demetra Spine represents a major step in scaling the company’s legacy into the spinal health space. Leveraging its scientific, technological, and engineering strengths, Demetra is poised to offer spine surgeons transformative tools tailored for both high-acuity hospitals and fast-paced outpatient environments.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
]]>Despite decades of research, the overall survival (OS) rate for advanced ovarian cancer has remained stagnant, largely due to its recurring nature. While nearly 80% of patients respond well to initial chemotherapy and surgeries, many experience relapse until now, with little explanation as to why.
A new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, sheds light on the mystery by identifying a previously overlooked threat: Minimal Residual Disease (MRD).
Hidden Cancer Cells Detected Despite Clean Scans
Led by TeamLab, a collaborative effort including the University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering, Johns Hopkins, Dana-Farber, and MIT’s Koch Institute, the study found that nearly half of ovarian cancer patients in remission still harbor hidden cancer cells, even when imaging shows no signs of disease.
Using advanced proteomic profiling and spatial transcriptomics, researchers analyzed MRD samples in unprecedented detail. They identified several druggable targets and uncovered biological pathways such as immune evasion, epithelial-mesenchymal transition, and hypoxia signaling that may allow cancer cells to survive treatment and evade detection.
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Breakthrough Blood Test Offers Hope
A major part of the study focused on circulating tumor DNA (ctDNA) tiny fragments of cancer DNA in the bloodstream as a minimally invasive tool to detect MRD. The use of ctDNA offers a powerful way to monitor disease progression, personalize treatment, and detect recurrence without the need for additional surgery.
“This research represents a critical shift in how we understand and monitor ovarian cancer,” said a spokesperson from TeamLab. “It’s not just about what we can see on scans, but what we’re missing at the molecular level.”
Second-Look Laparoscopy Reveals What Scans Miss
The researchers also employed a less invasive surgical technique called second-look laparoscopy (SLL) after chemotherapy and blood testing. Despite scans showing no evidence of disease, SLL revealed that 42% of patients still had lingering cancer cells, proving that conventional tests often miss MRD.
This study is part of a broader effort to understand MRD across multiple cancer types, including ALK-positive lung cancer and acute myeloid leukemia. Ongoing clinical trials are now using MRD detection as a primary endpoint, testing new immunotherapies aimed specifically at eradicating these hidden cancer cells.
Outlook
With MRD emerging as a critical factor in ovarian cancer recurrence, the research opens new doors for drug development and early intervention strategies
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
]]>Glioblastoma, a highly aggressive and life-threatening brain cancer, accounts for nearly half of all primary malignant brain tumors. With a median survival rate of just 14.6 months, the condition has long posed a challenge for researchers and drug developers. While only two drugs Merck’s Temodar (temozolomide) and Roche’s Avastin (bevacizumab) have made significant headway in the past two decades, recent pharmaceutical moves signal a shift in momentum.
Pharma Reinvests in a Once-Stalled Battle
In October 2024, Merck made headlines by acquiring Modifi Biosciences in a deal worth up to $1.3 billion. The biotech firm specializes in DNA modification for cancer therapeutics, including GBM. In a parallel move, Jazz Pharmaceuticals acquired Chimerix for $925 million this March, aiming to advance its pipeline with Chimerix’s diffuse glioma candidate. Jazz is now awaiting a crucial FDA decision on its promising drug candidate, dordaviprone, expected later this month.
These strategic acquisitions mark a resurgence in industry support after years of limited progress. Despite over 1,500 glioma trials registered between 2006 and 2021, the field struggled to deliver breakthrough treatments often due to insufficient funding and investor retreat.
A Push from Nonprofits and Early-Stage Innovators
The renewed funding is not solely pharma-driven. Nonprofits and early-stage innovators have played a critical role in maintaining momentum for glioblastoma research. Advocacy groups have contributed to the steady emergence of new funding streams and research collaborations, ensuring that scientific innovation continues despite previous setbacks.
Yash Thukral, Co-Executive Director of Innovate GBM, emphasized the difficulty of sustaining interest in such a challenging therapeutic area. “When the big pharma walks out, institutional investors walk out too because there’s no other option for them. If an institution doesn’t invest in the idea, then retail investment is not possible,” he said. “So, the companies working in the space don’t receive much capital and end up being forgotten in the big pharma race.”
Become a valued research partner with us – https://www.towardshealthcare.com/schedule-meeting
Marianne Baker, Science Engagement Manager at Cancer Research UK, highlighted the scientific complexity of glioblastoma. “Considering the location of the tumors and the biology of the brain, it is obvious that there are different types of cells and these grow tumors quickly, which makes it difficult to treat,” she explained. “The real challenge is these tumors are not visible and so not addressed quickly.”
Outlook
While glioblastoma remains a formidable challenge, the return of major pharmaceutical investment, combined with persistent nonprofit support, offers renewed hope. As new drugs inch closer to approval and research funding gains traction, the tide may finally be turning in the fight against this devastating disease.
Access our exclusive, data-rich dashboard dedicated to the healthcare market – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
]]>